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The primary aim of the audit described was to examine antiepileptic drug use among adult in-patients with learning disability. A
secondary aim was to examine investigation in those patients. For the purposes of this paper ‘Learning disability’ is synonymous
with ICD-10 ‘Mental Retardation’, ‘Mental Handicap’ or ‘Intellectual Impairment’ and should not be confused with the North
American use of the term which refers to discrete, specific problems in mental abilities such as reading. A total of 75 adult
patients on both the Northgate and Prudhoe sites (managed by Northgate and Prudhoe NHS Trust) were identified as being
treated with antiepileptic drugs (AEDs) for postulated epilepsy. Only 12 (16%) patients were being treated with three AEDs or
more, the remainder being on either one or two AEDs. All patients with a history of status epilepticus were prescribed rectal
diazepam or, more rarely, intranasal midazolam. The number and type of investigations performed on patients varied widely
and was sometimes limited by the patient’s ability to co-operate with procedures. Overall, 28 patients were identified who might
benefit from a reduction in the number of AEDs prescribed. In 15 of these patients antiepileptic drug regime was currently being
reduced. The increased utilization of sleep/sedated electroencephalogram (EEG) and magnetic resonance imaging (MRI— for
partial seizures), where practical, may also increase diagnostic accuracy in identifying epilepsy and its aetiology. Audit will be
repeated in 12 months.
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INTRODUCTION
Epilepsy is one of the most frequently occurring addi-
tional handicaps in people with learning disability1, 2.
The risk of ‘active’ epilepsy in a non-learning dis-
abled population has been estimated at 0.5%3. In those
with a mild to moderate learning disability (IQ 35–
70) this rises to 7%. In those with a severe or pro-
found learning disability (IQ 34 and below) and a
physical impairment the risk of active epilepsy has
been estimated as high as 67%2. Associations between
aggression/challenging behaviour, mental illness and
epilepsy have also been described4.
It is clear therefore that the treatment of epilepsy
forms an important aspect of patient management
in the learning disabled population. Over the last
decade there has been an expansion in the number
of antiepileptic drugs (AEDs) available. Doctors must
use these preparations in a rational and cost-effective
way, maximizing benefit and minimizing adverse re-
actions.
There are currently approximately 300 mainly adult
in-patients within the various specialized psychiatric
and continuing care services at Northgate and Prud-
hoe NHS Trust. Many of these patients are receiving
AEDs, some for reasons other than epilepsy (e.g. chal-
lenging behaviour, mood disorders). This audit project
mainly considers the prescribing pattern of AEDs for
epilepsy in the adult in-patients with learning disabil-
ity. Data on the number and type of investigations for
epilepsy were also collected.
The standards for this audit were difficult to estab-
lish given the dearth of large AED trials in this pop-
ulation. Standards were formulated which were partly
extrapolated from studies performed in non-disabled
adults with epilepsy. It is acknowledged that, given the
wide inter-individual variation of this heterogeneous
population, there may be many exceptions to any stan-
dards set.
Available evidence favours the use of monotherapy
with variable but modest gains from the addition of
a second AED in refractory cases. Figures quoted by
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studies are typically in the range of 20–30% reduction
in seizure frequency by the addition of a second AED
in refractory cases5, 6. There is currently no evidence
that using more than two AEDs decreases seizure fre-
quency in treatment resistant cases. However, the num-
ber of adverse reactions increases with the number of
antiepileptic drugs prescribed6, 7. Given current avail-
able data, pharmacodynamic and pharmacokinetic in-
teractions between two AEDs can be predicted with
limited accuracy. However when using three or more
antiepileptic drug medications such interactions are
very complex, and in practice, impossible to foresee.
In this population there are also potential interactions
with psychotropic and other medications which the
patient may be taking, further increasing the risks of
adverse effects.
Sodium valproate and carbamazepine are recom-
mended for initial first-line treatment of epilepsy in
this population for several reasons:
1. Both drugs have been extensively used over the
last 30 years and most of their side-effects are
familiar.
2. No new AED has been demonstrated to be su-
perior to either drug in terms of efficacy8, 9.
3. Both drugs are substantially less expensive than
the new generation of antiepileptic drugs10.
Earlier evidence favouring carbamazepine for par-
tial seizures has not been borne out by more recent
studies11. Smith’s 1987 study of AED treatment12 in
US veterans has been criticized for being too specific
to the treatment of seizures in older males. In addi-
tion it has been suggested that the study was biased
in favour of carbamazepine13. Patients were excluded
from Smith’s study if they had failed to respond to
carbamazepine previously. However such an exclusion
for valproate was not relevant as this drug was not li-
censed for the treatment of epilepsy in the US at that
time. Phenytoin, whilst still widely used first-line by
some neurologists, is associated with a deterioration
in cognitive functioning in patients with learning dis-
abilities14. The standards for the audit are shown in
Table 1.
Patients with learning disability are more likely to
experience multiple seizure types with earlier onset
than non-disabled patients with epilepsy. In addition
partial seizures may be more difficult to identify and
control is less likely to be established15, 16.
Table 1: Audit standards for the use of AEDs in adult
in-patients with epilepsy and learning difficultie .
1. Carbamazepine or sodium valproate should be used as initial
first-line except where there are specific clinical reasons for
use of an alternative AED.
2. The first-line antiepileptic drug should be increased to the
maximum tolerated dose, or alternatively, the recommended
dosage recommended by the BNF.
3. If seizure rate/severity is unchanged by the first-line
medication at maximally tolerated dosage an alternative
first-line medication may be started and a double taper
initiated whereby eventually monotherapy is attained 4.
4. If seizure rate/severity improves with first-line treatment but
complete remission is not achieved a trial of a second
antiepileptic drug may be used.
5. Patients with a history of status epilepticus should be
prescribed rectal diazepam or a reasonable alternative 5.
6. As a minimum standard, patients who are suspected of
suffering from epilepsy should have at least one standard
EEG.
7. Patients who are identified as experiencing partial seizures or
unexplained increase in seizure frequency should receive an
MRI scan where practical or when this is not possible a
computerized tomography (CT) scan of the head.
MATERIALS AND METHODS
The audit was carried out in May 2000, on 23 wards
which housed adult in-patients with learning disabil-
ities. All medication charts were examined to deter-
mine which patients were receiving antiepileptic drug
medication. Patients receiving medication for epilepsy
were identified by discussion with nursing staff and
examination of the case notes. In cases where nurs-
ing staff were unsure about the reason for antiepilep-
tic drug prescribing, inspection of past medical notes
clarified the purpose of the medication.
Once patients were identified as being treated for
epilepsy (either active or in remission) with antiepilep-
tic drugs their past medical and nursing notes were in-
spected and current drug regimen noted. Information
was extracted from the case notes (Table 2).
Whether a reduction in the number of, or dose of,
AEDs could be attempted was estimated using the fol-
lowing criteria:
1. No change in seizure frequency following addi-
tional medication.
2. No change in seizure frequency following in-
crease in dose.
3. Two or more AEDs being used at low dose.
RESULTS
Of 324 patients, 75 patients (23%) were identified as
suffering from epilepsy. The mean age was 38.6 years
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(±11.6). Twenty (26.7%) of the sample were female.
Of these 75 patients, 31 (41.3%) were in the mild
learning disability range, 19 (25.3%) were in the mod-
erate range, 19 (25.3%) were in the severe range with
only six (8%) of patients documented as having a pro-
found level of mental retardation.
In addition to an ICD-1017 diagnosis of mental
retardation all but 10 patients had additional speci-
fiers documented. The most common of these was be-
havioural problems (52 patients (69.3%)). In 13 cases
(17.3%) patients had physical conditions strongly as-
sociated with epilepsy (e.g. tuberose sclerosis).
In 12 (16%) patients it was not possible to define
seizure types. Forty-eight (64%) patients had been
recorded as experiencing generalized tonic–clonic
seizures in the past, although 32 of these also had other
types of seizure recorded (almost always including
complex partial). Thirty-seven had evidence of com-
plex partial seizures. Only 18 (28.6%) patients expe-
rienced one single seizure type with the majority of
patients suffering from multiple seizure types. There
was evidence that eight patients (10.7%) had suf-
fered from non-epileptiform attack disorder (NEAD—
formerly referred to as ‘pseudoseizures’) as well as
epilepsy. In addition, as a result of information ob-
tained during this audit, one patient received a diag-
nosis of factitious epilepsy and his treatment was sub-
sequently withdrawn.
There was a wide variation in seizure frequency; in
49 patients in whom seizures were still occurring and
where seizure frequency could be identified with rea-
sonable certainty the mean seizure frequency was 52.3
seizures per year (SD 122.5). These figures were dis-
torted by a small number of patients (N = 6) having
very frequent seizures (i.e. >100 per year). There was
evidence that 19 patients (25.3%) had been seizure
free for at least 1 year. In seven patients it was unclear
whether seizures were still occurring.
By definition all 75 patients were on at least one
AED. However in 11 patients it was not clear whether
the current regimen was also serving a dual purpose
of treating affective and/or behavioural disturbance.
Table 3 shows the number of patients on mono, dual,
triple or quadruple therapy. In total 12 patients (16%)
were on three or more AEDs. The commonest form of
dual therapy was a combination of sodium valproate
and carbamazepine. Sixteen patients were prescribed
this regimen. Of those 42 patients who were receiving
two or more drugs there was evidence that 22 had not
been tried on high dose monotherapy. The mean num-
ber of AEDs each patient was on was 1.7.
‘New’ (i.e. post-1985) antiepileptic drugs were be-
ing prescribed to 26 (34.7%) patients. Of these, six
patients were receiving two new antiepileptic drugs
whilst one patient was receiving a combination of
three. Chart 1 depicts the relative popularity of the
newer antiepileptic drugs being used, with lamotrigine
being the most popular.
Initial first-line treatment could be determined from
records in 61 patients. Twenty-four patients had been
initially treated with carbamazepine, 11 with sodium
valproate, four with phenytoin and 22 with either phe-
nobarbitone or primidone. Those patients started on
primidone or phenobarbitone all had been done so
more than 15 years ago. Thus all patients who have
been started on treatment in the last 5 years (where
this could be identified) were commenced on either
sodium valproate or carbamazepine first-line.
Table 2: Information extracted from the case notes.
1. Age.
2. Level of learning disability (ICD-10 16; mild, moderate,
severe, profound ‘mental retardation’) and IQ where
measured or estimated.
3. Current/previous psychiatric diagnoses (in addition to
ICD-10; mental retardation).
4. Physical diagnoses (including known cause of the learning
disability).
5. Seizure types identified.
6. The number of EEGs performed and whether these were
normal, abnormal or ambiguous.
7. Other investigations performed in establishing the diagnosis
of epilepsy or its aetiology (e.g. MRI, CT).
8. Current seizure frequency and worst documented seizure
frequency.
9. Evidence of a decreased seizure frequency with the last
modification to the AED regimen.
10. The current AED regimen.
11. The number of ‘new’ (>1985) antiepileptic drugs prescribed.
12. Status epilepticusa during the last year.
13. Rectal diazepam or substitute was currently prescribed.
14. Whether the above had been administered during the last year.
15. Which AED had been prescribed first-line.
16. Whether high-dose (BNF limit/maximum tolerated dose)
monotherapy had been attempted prior to the concurrent use
of two or more AEDs.
17. Time spent on current AED regimen.
18. Any side-effects noted on current regimen.
19. Evidence of an attempt to reduce the dose and/or number of
AEDs.
a For the purposes of this audit ‘status epilepticus’ is defined as a
seizure terminated after 5 min or more using as required
medication in addition to the more usual definition of continuous
seizure activity for 30 min or more.
Table 3: The number of patients concurrently taking different
numbers of AEDs.
Number of AEDs Number of patients
1 33 (44%)
2 30 (40%)
3 10 (13.3%)
4 2 (2.7%)
5 0 (0%)
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1
5
5
20
Lamotrigine
Tiagabine
Gabapentin
Topiramate
Fig. 1: Number of patients on each new AED.
Dosing regimens varied widely; nine patients were
on three times daily dosing of carbamazepine or
sodium valproate and two patients on four divided
doses of sodium valproate a day. The sustained release
preparations of these two drugs were given twice daily
even at total daily doses below 1500 mg.
Fifty-four patients (72%) were prescribed rectal di-
azepam ‘as required’ (PRN) for status epilepticus of
which eight had actually received it on at least one oc-
casion during the preceding 12 months. Six of these
patients had been reported as experiencing status in
the preceding 12 months and two patients had re-
ceived the medication as a precautionary measure after
seizures as they had a history of seizure clusters occur-
ring. In addition to rectal diazepam prescribing for sta-
tus, two patients had intranasal midazolam prescribed,
one patient had intranasal midazolam and rectal di-
azepam prescribed and one patient had rectal paralde-
hyde prescribed in addition to rectal diazepam. There
were no patients with a history of status epilepticus
who did not have such ‘as required’ medication pre-
scribed. Only nine (12%) patients were reported to be
currently suffering from possible side-effects of AED
treatment. These included ‘weight gain’ and hypona-
traemia.
There was wide variation in the number and type
of investigations performed. The average number of
standard EEGs performed was three per patient (SD
2.9). Seven patients had no record of an EEG trace
having been performed. In some cases this appeared
to be due to the inability of the patient to cooperate
with the investigation but it is likely that in the case of
patients who had been admitted from outside the re-
gion previous EEG records may have been lost. One
patient had 15 EEGs performed over a 45-year pe-
riod. Eleven patients (14.7%) had received CT scans
of the head with two having had failed attempts due
to poor co-operation. Six had received MRIs and one
had a failed attempt at an MRI scan due to poor co-
operation. Four patients with partial seizures had re-
ceived a CT scan whilst two had received an MRI. In
addition three patients had received both an MRI and
a CT scan for the investigation of partial seizures (in-
cluding one patient in whom clear images could not
be obtained). In three of these nine patients, imag-
ing revealed potentially treatable conditions associated
with seizures (the tubers of tuberose sclerosis, a sub-
dural haematoma and focal mesial temporal sclero-
sis).
DISCUSSION
Forty-four per cent of patients were being maintained
on monotherapy and only 16% of the studied popu-
lation were on three or more AEDs. However of the
patients who were receiving two or more drugs ap-
proximately half did not seem to have been tried on
high dose monotherapy. Thirteen patients (17%) were
identified as potentially benefiting from a reduction
in the number of AEDs they were prescribed. Fifteen
other patients were currently having a trial antiepilep-
tic drug reduction. Reynolds and Shorvon18 stressed
the benefits of monotherapy claiming to have 72%
of their non-disabled out-patients maintained on one
AED. Similarly, other authors have highlighted the
advantages of monotherapy and lower AED doses in
patients with learning disability15, 19.
All patients with a history of status epilepticus had
been prescribed rectal diazepam or an equivalent drug.
In recent years clinicians seem to be prescribing ei-
ther sodium valproate or carbamazepine first-line, us-
ing new AEDs as second-line or adjunct treatment.
Whilst some chronic patients are still being main-
tained on phenytoin and, occasionally, phenobarbi-
tone, neither drug appears to have been introduced as
a treatment for at least 5 years. Lamotrigine was found
to be the most widely selected ‘new’ AED. The rela-
tive popularity of this AED compared to other of the
more recently developed AEDs could be partly ex-
plained by the relatively lengthy amount of time it
has been available for (since 1985) and by the per-
ception by clinicians that it is generally well tolerated
in patients, the main side-effect being an associated
skin rash. This impression is supported by some ev-
idence that lamotrigine may have a lower rate of, at
least short-term, side-effects when compared to older
AEDs9 (e.g. Brodie et al.8).
There was a lack of consistency in the use of investi-
gations, even allowing for practical constraints. Whilst
in this audit a single standard waking EEG was set as
a standard, diagnostic accuracy can be improved by
the use of sleep deprived or sedated EEGs. This raises
sensitivity from around 50% to 80% from a single
recording20. The ILAE has published guidelines on
imaging, recommending MRI for those patients with
evidence of partial seizures21. Only around 24% of
patients with partial seizures received an MRI or CT
scan although this may be due to sound practical rea-
sons.
Approximately 75% of patients remained refrac-
tory to treatment. An identical proportion of refractory
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patients was found in a survey of adults with epilepsy
and learning disabilities in the county of Leicester16.
Also in agreement with this study was the high propor-
tion of patients experiencing multiple seizure types,
which similarly was more than half of the patients with
epilepsy.
The findings of this study provides evidence that
the standards set were appropriate and attainable in
the majority of this patient group. The findings of the
audit were presented at the appropriate meeting and
the results circulated to the appropriate staff. A repeat
of the audit will be performed to assess whether in-
creased adherence to the standards has occurred in the
mean-time and whether this results in an improvement
in patient wellbeing.
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